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PCLINICAL RESEARCH Clinical Trial
Effect of Intravenous Iron Sucrose on Exercise
Tolerance in Anemic and Nonanemic Patients With
Symptomatic Chronic Heart Failure and Iron Deficiency
FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial
Darlington O. Okonko, BSC, MRCP,* Agnieszka Grzeslo, MD,† Tomasz Witkowski, MD,†
Amit K. J. Mandal, MRCP,‡ Robert M. Slater, MBBS,‡ Michael Roughton, MSC,*
Gabor Foldes, MD, PHD,* Thomas Thum, MD,*§ Jacek Majda, MD,†
Waldemar Banasiak, MD, PHD,† Constantinos G. Missouris, MD,‡
Philip A. Poole-Wilson, MD, FMEDSCI,* Stefan D. Anker, MD, PHD,* Piotr Ponikowski, MD, PHD†
London and Slough, United Kingdom; Wroclaw, Poland; and Würzburg and Berlin, Germany
Objectives We tested the hypothesis that intravenous iron improves exercise tolerance in anemic and nonanemic patients
with symptomatic chronic heart failure (CHF) and iron deficiency.
Background Anemia is common in heart failure. Iron metabolism is disturbed, and administration of iron might improve both
symptoms and exercise tolerance.
Methods We randomized 35 patients with CHF (age 64  13 years, peak oxygen consumption [pVO2] 14.0  2.7 ml/kg/
min) to 16 weeks of intravenous iron (200 mg weekly until ferritin 500 ng/ml, 200 mg monthly thereafter) or
no treatment in a 2:1 ratio. Ferritin was required to be 100 ng/ml or ferritin 100 to 300 ng/ml with transferrin
saturation 20%. Patients were stratified according to hemoglobin levels (12.5 g/dl [anemic group] vs. 12.5
to 14.5 g/dl [nonanemic group]). The observer-blinded primary end point was the change in absolute pVO2.
Results The difference (95% confidence interval [CI]) in the mean changes from baseline to end of study between the
iron and control groups was 273 (151 to 396) ng/ml for ferritin (p  0.0001), 0.1 (0.8 to 0.9) g/dl for hemo-
globin (p  0.9), 96 (12 to 205) ml/min for absolute pVO2 (p  0.08), 2.2 (0.5 to 4.0) ml/kg/min for pVO2/kg
(p  0.01), 60 (6 to 126) s for treadmill exercise duration (p  0.08), 0.6 (0.9 to 0.2) for New York
Heart Association (NYHA) functional class (p  0.007), and 1.7 (0.7 to 2.6) for patient global assessment
(p  0.002). In anemic patients (n  18), the difference (95% CI) was 204 (31 to 378) ml/min for absolute
pVO2 (p  0.02), and 3.9 (1.1 to 6.8) ml/kg/min for pVO2/kg (p  0.01). In nonanemic patients, NYHA func-
tional class improved (p  0.06). Adverse events were similar.
Conclusions Intravenous iron loading improved exercise capacity and symptoms in patients with CHF and evidence of abnormal
iron metabolism. Benefits were more evident in anemic patients. (Effect of Intravenous Ferrous Sucrose on Exercise
Capacity in Chronic Heart Failure; http://www.clinicaltrials.gov/ct/show/NCT00125996; NCT00125996) (J Am Coll
Cardiol 2008;51:103–12) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.036i
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axercise intolerance is a cardinal feature of chronic heart failure
CHF), related to a poor quality of life and a heightened risk
f morbidity and mortality (1,2). Therapeutic options for
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nd manuscript. Drs. Okonko and Grzeslo monitored the trial. All authors were 2ncreasing functional capacity are limited, and additional strat-
gies are urgently required (3–6). A hallmark feature of
xercise in CHF is the early onset of anaerobic metabolism
nvolved in data acquisition, data analysis, and review of the manuscript. Drs.
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Iron Therapy in Heart Failure January 15, 2008:103–12as a consequence of impairments
in skeletal muscle oxygenation
and oxidative capacity that are
unrelated to central hemody-
namics (7,8). Targeting abnor-
malities that plausibly hinder
oxygen transportation and/or
utilization may confer functional
benefits.
Iron is critical for oxidative
metabolism, being an obligate
component of hemoglobin (Hb;
oxygen transport), myoglobin
oxygen storage), and the cytochromes and iron-sulphur
roteins of the Krebs cycle and electron transport chain
oxidative phosphorylation) (9–13). Anemia due to iron
eficiency impairs oxygen-carrying and tissue oxidative
apacity, resulting in a diminished peak oxygen consump-
ion (pVO2) and ability to endure submaximal exertion
14–17). Even in the absence of anemia, iron deficiency can
ttenuate exercise performance (18,19). In both anemic and
onanemic iron-deficient but otherwise healthy cohorts,
ron repletion has been shown to promptly correct func-
ional deficits. The magnitude of benefit often exceeds the
rythropoietic response (9,14–16,19,20).
Anemia is common in patients with CHF, but distin-
uishing iron-deficiency anemia (absolute iron deficiency)
rom the anemia of chronic disease (relative iron deficiency)
s notoriously difficult (12,21–24). Nanas et al. (22) found
hat 73% of patients with advanced heart failure and anemia
ad depleted iron stores on bone marrow aspiration. In a
ecent observational study, Bolger et al. (25) reported that
ntravenous (IV) iron sucrose alone increased exercise ca-
acity and reduced symptoms in CHF. Treatment with
ecombinant erythropoietin and adjuvant IV iron sucrose
ncreases exercise capacity in patients with CHF and anemia
26,27).
We designed and undertook a randomized controlled
rial (FERRIC-HF [Ferric Iron Sucrose in Heart Failure])
o test the hypothesis that iron repletion alone would
mprove exercise tolerance in anemic and nonanemic pa-
ients with symptomatic CHF and iron deficiency.
ethods
tudy design. The FERRIC-HF trial was a prospective,
andomized, open-label, observer-blinded, parallel, controlled
rial conducted at 2 centers: Wexham Park Hospital, Slough,
nited Kingdom, and Fourth Clinical Military Hospital,
roclaw, Poland. The study consisted of a 2-week initial
ssessment period and a 16-week treatment phase, with final
ssessments made 2 weeks later at week 18. The trial was
erformed in compliance with the International Conference on
armonization Guidelines for Good Clinical Practice and the
eclaration of Helsinki. The relevant ethics and research
Abbreviations
and Acronyms
CHF  chronic heart failure
Hb  hemoglobin
IV  intravenous
NYHA  New York Heart
Association
TSAT  transferrin
saturation
pVO2  peak oxygen
consumptionovernance committees approved the protocol. Written in- aormed consent was obtained from all patients before
nrollment.
tudy patients. Eligibility criteria were age21 years; symp-
omatic CHF (New York Heart Association [NYHA] func-
ional class II or III); exercise limitation as evidenced by a
eproducible pVO2/kg18 ml/kg/min during screening; aver-
ge of 2 screening Hb concentrations 12.5 g/dl (anemic
roup) or 12.5 to 14.5 g/dl (nonanemic group); ferritin
100 g/l or between 100 g/l and 300 g/l with a
ransferrin saturation (TSAT) 20%; left ventricular ejec-
ion fraction 45% measured within the preceding 6
onths using echocardiography or magnetic resonance
maging; use of maximally tolerated doses of optimal CHF
herapy for at least 4 weeks before recruitment and without
ose changes for at least 2 weeks; resting blood pressure
160/100 mm Hg; and normal red cell folate and vitamin
12 (according to local laboratory reference ranges).
Exclusion criteria included the use of erythropoietin, iron
oral or IV), or blood transfusion within the previous 30
ays; a history of acquired iron overload or hemochroma-
osis (or a first relative with hemochromatosis); earlier
ypersensitivity to parental iron preparations or a history of
llergic disorders; active infection, bleeding, malignancy, or
emolytic anemia; presence of any condition that precluded
xercise testing, such as decompensated heart failure, sig-
ificant musculoskeletal disease, unstable angina pectoris,
bstructive cardiomyopathy, severe uncorrected valvular dis-
ase, or uncontrolled brady- or tachyarrhythmias; concur-
ent immunosuppressive or renal replacement therapy; and
hronic liver disease (alanine transaminase 3 times the
pper limit of the normal range).
andomization. Qualifying patients were randomly as-
igned in a 2:1 ratio to receive 16 weeks of IV iron sucrose
r to the control group. All patients continued to receive
ptimal conventional treatment for CHF. Computer-
enerated randomization was within each center, using
andom permuted blocks of 6 within each Hb strata.
atients were stratified according to Hb levels (12.5 g/dl
s. 12.5 to 14.5 g/dl). Treatment allocation was concealed
rom the investigators involved in cardiopulmonary exercise
esting and echocardiography.
tudy drug and dosing schedule. Iron sucrose (Venofer;
ifor International, St. Gallen, Switzerland) was provided
s a solution for IV infusion in 5-ml ampules (20 mg
ron/ml). The treatment group received iron weekly (ther-
peutic phase) unless ferritin was 500 ng/ml and then at
eeks 4, 8, 12 and 16 (maintenance phase). The total dose
f iron was estimated as body weight (kg)  2.4  (15 
atients’ Hb [g/dl])  500 mg (for stores) (25). Each dose
as administered as 200-mg aliquots in 50 ml normal saline
nfused over 30 min. A test infusion (10 ml over 10 min)
as performed before the first treatment. Patients were
bserved for drug reactions for up to 1 h after all visits.
lood pressures were monitored before and 15 and 30 min
fter the initiation of infusions.
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January 15, 2008:103–12 Iron Therapy in Heart Failureatient follow-up. All patients were scheduled to be seen
t 1, 4, 8, 12, 16, and 18 weeks after randomization. At all
isits, a clinical examination was undertaken and blood
aken to measure Hb, urea, creatinine, alanine transaminase,
-reactive protein, serum iron, total iron binding capacity,
erritin, and transferrin. The TSAT was calculated (100 
erum iron/total iron-binding capacity). Iron therapy was
ithheld if ferritin was500 ng/ml, or Hb was16.0 g/dl,
r TSAT was 45% at any stage. Treatment was reinsti-
uted 2 weeks later if ferritin was 500 ng/ml, Hb was
16.0 g/dl, and TSAT was 45%. At baseline and end of
tudy, levels of soluble transferrin receptor (Dade Behring,
arburg, Germany) and malondialdehyde (Pharmacia
KB, Freiburg, Germany), a marker of lipid peroxidation,
ere quantified (28). Patients were formally referred to a
astroenterologist who decided on the appropriateness of
urther diagnostic tests. Patients randomized to the control
roup were offered IV iron therapy at the end of the study
f clinically appropriate.
nd points. The primary end point for efficacy was the
hange in absolute pVO2 (ml/min) from baseline to week 18.
rospectively defined secondary efficacy outcomes included
hanges from baseline to week 18 in pVO2 (ml/kg/min)
djusted for body weight, exercise duration, Hb, ferritin,
SAT, soluble transferrin receptor, left ventricular ejection
raction, changes from baseline to week 8 to 18 in NYHA
unctional class, patient global assessment on a 7-point scale
4), Minnesota Living With Heart Failure Questionnaire
MLHFQ) score, and fatigue score (assessed using a 10-
oint visual analog fatigue scale, ranging from 1 for no
atigue to 10 for very severe fatigue) (20).
Exercise testing was performed on a treadmill using a
odified Naughton or modified Bruce protocol depending
n the physician’s judgement (2,3). During screening, each
atient underwent a minimum of 2 tests separated by a
eek. Ventilation, oxygen uptake, and carbon dioxide pro-
uction were monitored on a breath-by-breath basis and
veraged over 15-s intervals. Peak VO2 (ml/min) was mea-
ured as an average of the last 15 s of exercise. Maximal
xercise capacity was attained if the respiratory exchange
atio had reached 1.00 or had increased by a minimum of
.15 from the resting value.
End points for tolerability included all adverse events,
erious adverse events (including deaths and hospitalizations
24 h in duration), changes in mean arterial blood pressure
t 15 and 30 min after IV iron infusion, episodes of anaphylaxis
r symptomatic hypotension during IV iron infusion, episodes
f hyperferritemia (500 ng/ml), and changes in vital signs
systolic and diastolic blood pressure, heart rate), alanine
ransaminase, urea, creatinine, C-reactive protein and malon-
ialdehyde from baseline to week 18. All serious adverse
vents were reported to an independent safety officer and
he appropriate research governance committee within 24 h
f occurrence.
tatistics. The statistical analyses were pre-specified andollowed the intention-to-treat principal using the last 1bservation carry-forward method for imputing missing
ata. Sample size estimates assumed an average baseline
VO2/kg of 15 ml/kg/min, with a standard deviation (SD)
f difference in pVO2/kg of 2.0 ml/kg/min (4) and a desired
reatment effect of 2.1 ml/kg/min. Adjusting for unequal
ampling (2:1) and a 10% rate of attrition, we calculated that
6 patients (24 IV iron group, 12 control group) were
eeded (alpha  0.05; beta  83%).
The primary analysis was an unpaired comparison of the
hanges in absolute pVO2 (ml/min) between the treatment
rms using the Student t test. Paired changes from baseline
o week 18 were assessed using paired t tests. Data are
resented as mean  SD. Summary statistics include the
oint estimates of week 18 pVO2, the change from
aseline to week 18, and the estimates and 2-sided 95%
onfidence intervals (CI) for the difference between least-
quares means of the 2 treatment arms. All other continuous
nd points were analyzed in a similar fashion. Categoric
ariables were evaluated using a chi-square or Fisher exact
est. The relations between variables were evaluated using
earson correlation coefficient. Adjusted analyses were per-
ormed by analysis of covariance modeling including, where
ppropriate, interaction terms in the model. All statistical
ests were 2 sided, and we judged a p value of 0.05 to be
ignificant. All analyses were carried out using Stata 9.2
Stata Corp., Dallas, Texas) and Statview 4.5 for Windows
Abacus Concepts, Berkeley, California).
esults
atients and iron treatment. Between July 2004 and
ctober 2005, we randomized 35 (14 British and 21 Polish)
atients to IV iron (n  24) or control (n  11) (Fig. 1).
aseline characteristics were similar between groups (Table 1).
n the control group, 8 were male and 3 female. In the group
eceiving IV iron, 17 were male and 7 female. Of the 18
lassified as anemic, 11 were male and 7 female. In the
onanaemic group, 14 were male and 3 female.
Four treated patients (16%) terminated the study early
ecause of death (n  1) or withdrawal of consent (n  3).
ne control patient (9%) withdrew consent early. Conse-
uently, 14% of the data analyzed was imputed. Sensitivity
nalyses conducted without imputation for missing values
ielded consistent results.
The mean weight at baseline in the control group was
4.3  14.9 kg and in the treated group 75.9  17.4 kg
p  0.18). During the trial weight significantly increased
y 2.7 kg in the control group and decreased by 1.8 kg in the
reated group (p  0.004) (Table 2).
The mean iron repletion dose was 928  219 mg in the
verall population, 1,051  219 mg in anemic patients, and
81  94 mg in nonanemic patients. The total dose of IV
ron administered was 1,433  365 mg in the overall
opulation, 1,583  366 mg in anemic patients, and
,269  297 mg in nonanemic patients.
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Iron Therapy in Heart Failure January 15, 2008:103–12ffect of IV iron on iron status and hemoglobin. ALL PA-
IENTS. Ferritin and TSAT significantly increased only in
he IV iron group (Table 2). Soluble transferrin receptor
evels did not change significantly in either the control or
he treated group. Iron therapy resulted in a significant
reatment effect (95% CI) on ferritin (273 [151 to 396]
g/ml; p  0.001), TSAT (11% [5% to 17%]; p  0.001)
nd soluble transferrin receptor (0.3 [0.6 to 0.01]
g/l; p 0.046). The Hb levels significantly increased from
aseline in the iron group. The treatment effect (95% CI)
as 0.1 [0.8 to 0.9] g/dl (p  0.2). Adjustment for center
ad no impact (p  0.50) for all end points. Adjustment for
enter and Hb strata together did not alter the results (p 
.12 for all interactions).
NEMIC AND NONANEMIC SUBGROUPS. In anemic and
onanemic patients, ferritin and TSAT significantly in-
reased in the iron group and remained unchanged in the
ontrol group (Table 3). There were no changes in Hb or
oluble transferrin receptor levels in either of the subgroups.
ffect of IV iron on exercise tolerance. ALL PATIENTS.
n patients receiving IV iron there was a trend toward an
mprovement in exercise tolerance as measured by absolute
VO2 (p 0.08) (Table 2). The mean treatment effect (95%
I) from baseline to week 18 between the iron and control
roups was 96 [12 to 205] ml/kg. Absolute pVO2 signif-
cantly increased in the iron group and remained unchanged
n the control group (Fig. 2A).
Similarly, pVO2/kg (Fig. 2B) and exercise duration in-
Figure 1 Trial Profile
Hb  hemoglobin; IV  intravenous; TSAT  transferrin saturation.reased in the iron group and remained unchanged in the
Dontrol group. The treatment effect (95% CI) was signifi-
ant for pVO2/kg (2.2 [0.5 to 4.0] ml/kg/min; p  0.01).
here was a trend toward an improvement in absolute
xercise duration (60 [95% CI 6 to 126] s; p  0.08) and
he percentage change in exercise duration from baseline
17% [95% CI 3% to 36%]; p  0.09) was shown.
aution is needed in interpreting exercise duration data,
ecause 2 different exercise protocols were used as appro-
riate. Post-exercise respiratory exchange ratios were similar
n treated and control patients (1.10 0.16 vs. 1.04 0.12;
 0.26).
Significant interactions between treatment allocation and
b strata (all p  0.03), but not center (all p  0.50), were
vident for pVO2 and pVO2/kg. Adjustment for Hb strata
nd center together did not alter exercise duration findings
p  0.55 for all interactions).
Changes in pVO2 did not relate to changes in Hb
Fig. 3A) but to increases in TSAT in iron-treated (r 
.45; p 0.03) but not control (r 0.04; p 0.90) patients
Fig. 3B).
NEMIC AND NONANEMIC SUBGROUPS. Iron significantly
mproved absolute pVO2 (204 [95% CI 31 to 378] ml/min;
 0.02) and pVO2/kg (3.9 [95% CI 1.1 to 6.8] ml/kg/min;
 0.009) in anemic but not in nonanemic patients (Table
). Adjustment for baseline pVO2 or pVO2/kg did not alter
he results (p  0.44 for all interactions). Iron had no
ignificant effects on exercise duration in either of these
ubgroups. Changes in pVO2 were related to changes in
SAT (but not Hb) in anemic patients (n  18; r  0.62;
 0.006).
aseline Characteristics
Table 1 Baseline Characteristics
Control (n  11) IV Iron (n  24)
Demographics and clinical, n (%)
Age (yrs), mean  SD 62 11 64 14
Male gender 8 (73) 17 (71)
Caucasian race 10 (91) 21 (88)
Body mass index (kg/m2) 28  5 26  5
Ischemic etiology 8 (73) 18 (75)
NYHA functional class
II 6 (55) 13 (54)
III 5 (45) 11 (46)
Comorbidities
Coronary artery disease 8 (73) 19 (79)
Hypertension 5 (45) 12 (50)
Diabetes 4 (36) 8 (33)
Hyperlipidemia 5 (45) 7 (29)
Treatment
Diuretics 8 (73) 17 (71)
ACE inhibitors 8 (73) 18 (75)
Angiotensin II antagonists 2 (18) 5 (21)
Beta-blockers 11 (100) 20 (83)
Spironolactone 6 (55) 11 (46)
Digoxin 2 (18) 6 (25)ata are presented as number of patients (%).
ACE  angiotensin-converting enzyme; IV intravenous; NYHA  New York Heart Association.
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January 15, 2008:103–12 Iron Therapy in Heart Failureffect of IV iron on symptoms and quality of life. ALL PA-
IENTS. Patients treated with IV iron had a significant
mprovement in NYHA functional class at week 18 (Table
) (Fig. 4B). The NYHA functional class improved in 8
atients (44%) in the iron group versus 0 patients in the
ontrol group (p  0.03). A consistent improvement in
atient global assessment, fatigue score, and MLHFQ score
rom baseline to weeks 8 and 18 was observed only in the
ron group (Figs. 4A, 4C, and 4D).
NEMIC AND NONANEMIC SUBGROUPS. In anemic patients,
ron significantly improved NYHA functional class at week
8 (Table 3). In nonanemic patients, a trend toward an
mprovement in NYHA functional class was observed.
olerability and adverse events. Adverse event profiles
ere similar between the treatment arms (Table 4). Ten
42%) and 7 (64%) adverse events occurred in the iron and
ontrol groups, respectively. All events were unrelated (76%)
r unlikely to be related (24%) to the study. Three hospi-
alizations (12%) occurred in the iron group for cardiac
ecompensation, severe abdominal pain, and poorly con-
rolled hyperthyroidism. Three (27%) hospitalizations oc-
urred in the control group due to cardiac decompensation
n  2) and cardioverter-defibrillator implantation. One
nd Points for Total Population
Table 2 End Points for Total Population
Baseline E
Control
(n  11)
IV Iron
(n  24)
Contr
(n  1
Primary end point
Absolute peak VO2 (ml/min) 1,201 330 1,053 321 1,180
Secondary end points
Peak VO2/kg (ml/kg/min) 14.2 3 13.9 2.7 13.5
Exercise duration (s) 501 179 476 185 486
Transferrin saturation (%) 21 9 20 8 23
Ferritin (ng/ml) 88 62 62 37 139
Soluble transferrin receptor (mg/l) 1.6 0.6 1.4 0.4 1.8
Hemoglobin (g/dl) 12.2 1 12.6 1.2 12.6
Jugular venous pressure (cm) 1.4 2.0 1.5 1.7 2.1
Weight (kg) 84.3 14.9 75.9 17.4 87.0
NYHA functional class 2.4 0.5 2.5 0.5 2.6
Patient global assessment — — —
MLHFQ score 46 18 41 22 49
Fatigue score 6 1 6 1 6
Left ventricular ejection fraction (%) 29 6 30 7 30
Safety end points
Systolic blood pressure (mm Hg) 116 18 120 22 115
Diastolic blood pressure (mm Hg) 70 9 69 9 71
Heart rate (beats/min) 67 6 74 10 75
Urea (mmol/l) 8.3 3.1 9.1 3.5 9
Creatinine (mol/l) 104 39 109 42 121
Alanine transaminase (iU/l) 22 16 22 13 22
C-reactive protein (mg/l) 3 2 6 7 7
Malondialdehyde (mol/l) 0.5 0.3 0.5 0.2 0.5
Values are expressed as mean SD. Treatment effect changes in IV iron group changes in co
ron using the Student t test. *p  0.05; †p  0.01; and ‡p  0.001 within-group differences co
IV  intravenous; MLHFQ  Minnesota Living With Heart Failure Questionnaire; NYHA  New Yeath, due to intractable cardiac pump failure, that was iudged to be unrelated to study drug, occurred in an anemic
reated patient (Fig. 1).
Reductions in mean arterial blood pressure occurred 15
in (3 [95% CI 4 to 1] mm Hg; p  0.003) and 30
in (2 [95% CI4 to 0] mm Hg; p 0.01) after IV iron
nfusion, but no episodes of symptomatic hypotension or
naphylactic reactions occurred. Nineteen episodes of tran-
ient hyperferritemia were recorded. Iron did not signifi-
antly alter renal and liver function tests or C-reactive
rotein and malondialdehyde levels (Table 2). In anemic
atients, a significant increase in heart rate occurred in
ontrol but not iron-treated subjects and was associated with
significant treatment effect (Table 3).
iscussion
he major finding of this study is that, in symptomatic
atients with CHF and abnormal indices of iron metabo-
ism suggestive of possible iron deficiency, treatment with
V iron was well tolerated and associated with significant
mprovements in maximal exercise capacity as quantified by
VO2/kg. Trends for an increase in absolute pVO2 and
xercise duration were found. Functional benefits were
aralleled by significant improvements in symptoms and
Study Change  SD
Treatment Effect
(95% CI) p Value
IV Iron
(n  20) Control IV Iron
1,128 303 21 120 75 156* 96 (12 to 205) 0.08
15.4 3.5 0.7 1.4 1.5 2.7* 2.2 (0.5 to 4.0) 0.01
521 186 15 109 45 84* 60 (6 to 126) 0.08
33 10 2 7 13 9‡ 11 (5 to 17) 0.001
386 208 51 85 324 189‡ 273 (151 to 396) 0.001
1.3 0.4 0.2 0.6 0.1 0.3 0.3 (0.6 to0.01) 0.046
13.2 1.1 0.4 0.9 0.5 1.2* 0.1 (0.8 to 0.9) 0.87
1.4 1.7 0.7 1.4 0.1 0.7 0.8 (1.5 to0.1) 0.03
74.1 16.1 2.7 4.0* 1.8 3.9* 4.6 (7.5 to1.6) 0.003
2.1 0.5 0.2 0.4 0.4 0.6* 0.6 (0.9 to0.2) 0.007
— 0.2 1.6 1.5 1.2 1.7 (0.7 to 2.6) 0.002
31 25 3 19 10 18* 13 (26 to 1) 0.07
4 2 0 2 2 2* 2 (3 to1) 0.004
32 10 1 5 2 5 1 (3 to 4) 0.66
119 20 1 17 1 12 0 (10 to 10) 0.98
69 8 1 15 0 9 1 (8 to 6) 0.73
75 11 8 7† 1 11 7 (14 to 1) 0.08
8.5 2.6 0.7 5.3 0.6 2.5 1.3 (4.0 to 1.3) 0.32
110 39 17 49 1 29 16 (43 to 11) 0.23
27 14 0 10 5 17 5 (6 to 16) 0.34
6 8 4 9 0 8 4 (10 to 2) 0.24
0.5 0.2 0 0.3 0 0.2 0 (0.2 to 0.1) 0.76
up. The p value represents unpaired comparison of the changes between control and intravenous
with baseline.
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Iron Therapy in Heart Failure January 15, 2008:103–12ore evident in anemic subjects, who demonstrated signif-
cant increases in both absolute pVO2 and pVO2/kg. Incre-
ents in pVO2 did not correlate to increments in Hb (blood
xygen content) but to increases in TSAT (circulating iron
tatus).
ron metabolism in heart failure. Defective iron supply
or erythropoiesis is an emerging feature of CHF (21), but
efining iron deficiency in this cohort is notoriously difficult.
erritin is the major iron storage protein, and in the absence
f inflammation, serum ferritin levels are the best noninva-
ive estimates of body iron stores (9). However, heart failure
s a state of chronic immune activation, and proteins such as
erritin are increased in the anemia of chronic disease (12).
hus, the use of biochemical markers and conventional
ut-offs derived from noninflammatory cohorts to identify
ron deficiency in CHF patients is questionable. Recently,
anas et al. (22) measured the iron content of bone marrow
iopsies in patients with advanced heart failure and anemia;
3% of patients had reduced iron stores. The mean ferritin
evels were 75 ng/ml in those who were iron deficient and
11 ng/ml in those not iron deficient. Bolger at al. (25)
eported a mean value of 87 ng/ml. These values are far
bove the 15 to 20 ng/ml cutoffs that are usually regarded as
ndicative of iron-deficiency anemia. Consequently, we used
igher ferritin cutoffs for iron deficiency to address its
mpact on exercise and symptoms in CHF.
ffect of IV iron in anemic patients. In this trial, iron
herapy led to an absolute mean increase of 204 ml/min
23%) and 3.9 ml/kg/min (30%) in pVO2 and pVO2/kg,
espectively. This represents a substantial benefit. In a
ingle-blind study of 26 anemic CHF patients, Mancini
nd Points for Anemic and Nonanemic Subgroups
Table 3 End Points for Anemic and Nonanemic Subgroups
Baseline W
Control IV Iron Control
Anemic patients
Absolute peak VO2 (ml/min) 1,224 314 880 259 1,178 269
Peak VO2/kg (ml/kg/min) 14.7 3.6 12.9 2.8 13.6 2.9
Exercise duration (s) 506 71 441 188 526 169
Transferrin saturation (%) 18 4 18 6 20 4
Ferritin (ng/ml) 91 58 44 33 132 88
Hemoglobin (g/dl) 11.4 0.7 11.7 1.0 12.0 1.0
NYHA functional class 2.5 0.5 2.4 0.5 2.7 0.8
Heart rate (beats/min) 66 8 77 8 75 10
Nonanemic patients
Absolute peak VO2 (ml/min) 1,174 382 1,226 288 1,183 409
Peak VO2/kg (ml/kg/min) 13.6 2.4 14.9 2.2 13.3 2.1
Exercise duration (s) 492 270 510 180 438 228
Transferrin saturation (%) 26 11 23 10 27 12
Ferritin (ng/ml) 86 72 81 32 148 166
Hemoglobin (g/dl) 13.1 0.3 13.6 0.6 13.3 1
NYHA functional class 2.4 0.5 2.6 0.5 2.6 0.9
Heart rate (beats/min) 69 4 70 11 75 11
Values are expressed as mean SD. Treatment effect changes in IV iron group changes in co
ron using the Student t test. *p  0.05; †p  0.01; and ‡p  0.001 within-group differences com
Abbreviations as in Table 2.t al. (3) reported an absolute mean increase of 2.2 ol/kg/min after recombinant erythropoietin and oral iron
nd folate therapy. In the MIRACLE (Multicenter
n-Sync Randomized Clinical Evaluation) and PATH-
HF (Pacing Therapies for Congestive Heart Failure)
tudies, cardiac resynchronization conferred absolute me-
ian increases in pVO2/kg of 0.9 and 1.7 ml/kg/min,
espectively (4,5). In trials evaluating exercise training,
ercentage increases from baseline in pVO2/kg have
anged from 12% to 31% (6).
The effect of IV iron on exercise performance likely
eflects its critical role in multiple facets of exercise physi-
logy and is corroborated by earlier analyses. Studies in
nimals and otherwise healthy human subjects have now
rmly established that iron-deficiency anemia attenuates
ndices of work capacity such as pVO2/kg by 10% to 50%
14,16,29). Such impairments are proportional to the sever-
ty of iron deficiency and improve with iron repletion, but
he magnitudes of benefit are often unrelated to the in-
reases in Hb (16).
Increments in pVO2 can be partly ascribed to an increase
n tissue iron delivery. Anemia due to iron deficiency
riggers excessive dyspnea (9), impairs neurotransmission
10,11), diminishes the oxygen-carrying capacity of both
lood (reduced Hb) and skeletal muscle (reduced myoglo-
in), and attenuates mitochondrial oxygen utilization (re-
uced aerobic enzyme activity) (13–15). The mechanism of
unctional benefit with iron might involve the alleviation of
ny or all of these features. Elegant animal experiments have
uggested that during iron repletion, improvements in Hb
nd pVO2 evolve in parallel, whereas enhancements in
ubmaximal (endurance) capacity track the increase in aer-
8 Change
Treatment Effect
(95% CI) p ValueIV Iron Control IV Iron
,038 324 46 116 158 182* 204 (31 to 378) 0.02
15.7 4.5 1.1 0.9* 2.8 3.2† 3.9 (1.1 to 6.8) 0.009
504 214 20 114 63 97 43 (66 to 153) 0.41
32 11 2 7 14 9‡ 12 (3 to 22) 0.01
343 199 41 79 299 187‡ 258 (87 to 429) 0.006
12.5 1.0 0.6 1.1 0.8 1.5 0.2 (1.3 to 1.7) 0.78
2.1 0.5 0.2 0.4 0.3 0.5* 0.5 (1.0 to 0) 0.048
73 10 9 5† 4 12 13 (24 to2) 0.02
,218 262 9 132 8 54 17 (110 to 76) 0.71
15.0 2.1 0.3 1.9 0.1 0.8 0.4 (0.9 to 1.7) 0.53
534 162 55 98 27 66 83 (3 to 169) 0.06
33 10 1 8 10 8† 9 (0 to 19) 0.046
430 217 62 100 349 197‡ 287 (87 to 487) 0.008
13.8 0.9 0.2 0.8 0.2 0.7 0 (0.9 to 0.8) 0.96
2.2 0.6 0.2 0.4 0.4 0.7* 0.6 (1.3 to 0.1) 0.08
76 12 6 9 6 8 0 (9 to 10) 0.97
up. The p value represents unpaired comparison of the changes between control and intravenous
with baseline.eek 1
1
1
ntrol grobic enzyme activity (14,30). This has not been a consistent
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January 15, 2008:103–12 Iron Therapy in Heart Failurending in humans (16), and in the present analysis we found
o correlation between changes in Hb and changes in pVO2.
lthough limited power may account for this, it is tenable
hat mechanisms unrelated to oxygen delivery (Hb levels)
ere operative. Data accrued over the last 3 decades have
ow firmly established that, in CHF, pVO2 at maximal
xercise is not immediately limited by defects in central
emodynamics but by muscle atrophy, signals from stretch
nd metabolic receptors, near-normal glycolytic but atten-
ated Krebs cycle enzyme activity, accelerated phosphocre-
tinine depletion, and early skeletal muscle acidosis on
xertion (7,8). Because skeletal muscle dysfunction in rats
endered iron deficient mirrors these abnormalities (14,15),
t is plausible that IV iron mediates functional effects at the
issue level by augmenting aerobic metabolism and muscle
xidative phosphorylation (13). Consistent with this, we
ound a significant correlation between changes in TSAT
nd changes in pVO2. The pilot nature of the present study
recludes definitive mechanistic inferences from being
ade.
Iron triggered early improvements in NYHA functional
lass, patient global assessment (8), and fatigue score (20). This
Figure 2 Individual Changes
in Exercise Tolerance With Iron Therapy
Treatment effect of intravenous (IV) iron on (A) absolute peak oxygen con-
sumption (VO2) and (B) peak VO2/kg in anemic (bold lines) and nonanemic
(dashed lines) subjects. Bars correspond to mean  SD.apid onset of symptomatic benefit is an established feature ofron therapy and is thought to have a neurologic basis (9–11).
dditionally, iron was associated with significant reductions in
ody weight. This may have been due to improvements in
emodynamic and/or neurohormonal status and may have
ontributed to exercise benefits. In contrast, the Hb response
as surprisingly suboptimal. Iron deficiency is a continuum
hich, at its extreme, manifests as anemia. If low Hb levels
ollow from isolated iron store depletion (absolute iron
eficiency), a 2-g/dl mean increase in Hb would be expected
fter 3 to 6 weeks of iron repletion (9). In the present study,
he mean increase in Hb was 0.8 g/dl. In the study by Bolger
t al. (25) the increase was greater, but the patients were
ore anemic at baseline. Pharmacokinetic analyses have
hown that after IV injection, iron preparations are initially
Figure 3 Correlates of Exercise Performance
Relation between changes in absolute peak oxygen consumption (VO2) and (A)
changes in hemoglobin concentration (r  0.17; p  0.43 for intravenous [IV]
iron group on removal of outlier [arrow]) and (B) changes in transferrin satura-
tion in the total population.
c
p
m
T
p
s
E
p
f
l
e
(
g
p
m
h
e
c
v
i
T
w
l
t
e
a
h
w
i
p
d
t
h
s
A
110 Okonko et al. JACC Vol. 51, No. 2, 2008
Iron Therapy in Heart Failure January 15, 2008:103–12leared from the plasma by macrophages, and in the
resence of inflammation the donation of infused iron from
acrophages to the erythroid marrow is blunted (31–33).
hus, chronic low-grade inflammation and our inclusion of
atients with mild anemia were possibly responsible for the
uboptimal Hb response.
ffect of IV iron in nonanemic patients. Nonanemic
atients derived no functional benefits from iron, but some
avorable trends on symptoms were observed. Lower Hb
evels are a surrogate for greater reductions in aerobic
nzyme activity that are difficult to quantify noninvasively
9). Thus, anemic patients would be expected to derive
reater functional benefits than their nonanemic counter-
arts irrespective of the erythropoietic response. Impair-
ents in oxygen utilization in nonanemic patients might
ave been sufficient to limit submaximal, but not maximal,
xertion. Indeed, substantial evidence suggests that iron
onfers inconclusive or no effects on pVO2 but improves
arious indices of submaximal endurance capacity and qual-
ty of life in nonanemic iron-deficient subjects (18–20,29).
olerability of IV iron. Iron repletion with IV iron sucrose
as well tolerated, without any clinical evidence of anaphy-
axis. The incidence of adverse events was similar between
he treatment arms. During 165 infusions, only 10 adverse
vents occurred in the iron group. The majority were minor
nd did not interrupt treatment. Although frequent mild
Figure 4 Effect of Iron Therapy on Symptoms and Quality of Lif
Effect of treatment on (A) visual analog fatigue score, (B) New York Heart Associa
With Heart Failure Questionnaire (MLHFQ) score in the total population. Data are sypotensive episodes occurred during iron infusions, none Iere associated with symptoms or tachycardia. Iron signif-
cantly reduced elevated heart rates in anemic patients,
ossibly by attenuating the stimulatory effects of iron-
eficiency anemia on catecholamine synthesis (9). Iron
herapy did not increase markers of inflammation or renal/
epatic dysfunction. Importantly, 16 weeks of IV iron
ucrose did not escalate levels of malondialdehyde, a marker
YHA) functional class, (C) patient global assessment, and (D) Minnesota Living
as mean  SD. *p  0.05; †p  0.01 compared with baseline.
dverse Events Profile
Table 4 Adverse Events Profile
Control
(n  11)
IV Iron
(n  24)
Patients with 1 or more adverse events, n (%) 7 (64) 10 (42)
Nonserious adverse events, n (%)
Abdominal pain 0 (0) 2 (8)
Coryzal symptoms 1 (9) 2 (8)
Cough 2 (18) 0 (0)
Gout 0 (0) 1 (4)
Transient ischemic attack 0 (0) 1 (4)
Heartburn 0 (0) 1 (4)
Pneumonia 1 (9) 0 (0)
Internal cardiac defibrillator implantation 1 (9) 0 (0)
Decompensated heart failure (nonhospitalized) 1 (9) 0 (0)
Serious adverse events, n (%)
Decompensated heart failure (hospitalized) 1 (9) 1 (4)
Symptomatic hyperthyroidism (hospitalized) 0 (0) 1 (4)
Death 0 (0) 1 (4)e
tion (N
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January 15, 2008:103–12 Iron Therapy in Heart Failuref lipid peroxidation. The adverse event rates seen in the
resent trial are similar to those listed in the medication’s
ackage insert (34). However, the present study was small
nd relatively short, restricting the ability to detect adverse
vents.
tudy limitations. The small sample size limits the power
o detect small differences between treatment groups. Al-
hough the open adjudication of secondary and safety end
oints escalates the risk of subject and/or investigator bias,
ur primary end point was objective, resistant to bias, and
lindly ascertained. Our ferritin cutoff for iron deficiency
100 ng/ml) was higher than that advocated by the World
ealth Organization (12 ng/ml). Chronic heart failure is
chronic inflammatory state, and higher ferritin cutoffs,
ven as high as200 ng/ml, provide optimal sensitivity and
pecificity for the detection of depleted iron stores in
nflammatory cohorts (9).
We used the last observation carry-forward method for
andling missing data. Stringent sensitivity analyses con-
rmed that the results were robust and not influenced by
mputation. Because anemia is associated with edema
ormation and its correction can lead to significant weight
eductions, absolute pVO2 was chosen as the primary end
oint to minimize the attribution of functional benefits to
eight changes. Owing to the lack of an appropriate
lacebo for IV iron, control patients in the United
ingdom received no treatment. The Ethics Committee
n Poland required that control patients receive IV saline.
djustment for center in statistical analyses did not affect
he results. Nevertheless, the benefit of iron treatment
id seem to be larger in the patients in the United
ingdom.
onclusions
he FERRIC-HF trial has shown that 16 weeks of IV iron
ucrose therapy is well tolerated and associated with im-
rovements in exercise capacity and symptom status in
atients with heart failure and iron deficiency. Benefits were
ore evident in anemic patients. Such outcomes, if repli-
ated in larger and longer studies in CHF cohorts, may
ender anemic and possibly nonanemic iron deficiency a
herapeutic target in this population. At present, this idea
emains unproven.
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